Elixinol Wellness Achieves Record $4.3 Million Revenue with Margin and Cash Flow Gains

Record Revenue Boosted by The Healthy Chef Expansion

Elixinol Wellness Ltd (ASX:EXL) reported a record quarterly revenue of $4.3 million for Q2 FY26, marking a 5% increase compared to the prior corresponding period. This milestone follows the company’s strategic transformation and portfolio restructuring, excluding legacy US CBD operations. The standout performer was The Healthy Chef brand, which grew revenue by 20% year-on-year and 26% quarter-on-quarter, now accounting for 27% of group revenue, up from 23% a year earlier. The brand’s expansion into Priceline Pharmacy has broadened its retail footprint, tapping into a high-traffic network and boosting consumer access.

Margin Expansion and Premium Product Focus

Gross margin expanded sharply to 45% in Q2 FY26, up 8 percentage points from 38% in the prior year quarter. This improvement reflects disciplined portfolio management, a shift towards higher-margin e-commerce sales, and reduced exposure to lower-margin contracts and SKUs. Gross profit rose 26% year-on-year to $2.0 million, largely driven by a 36% increase in the Australian business. The company’s focus on premium functional nutrition products, including Metabolic Burn and Protein Water, supports this margin uplift and aligns with its strategy to grow higher-margin revenue streams.

Operating Cost Cuts Drive Cash Flow Improvement

Operating expenses were slashed by 23% compared to the prior corresponding period, with notable reductions in employee costs (23%), distribution (25%), marketing (32%), and administration (15%). These cost savings contributed to a positive underlying operating cash flow of $50,000 for the quarter, marking the third consecutive quarter of positive cash flow on this basis. However, reported net operating cash outflow was $580,000 due to one-off items including AGM costs, out-of-cycle payments, and interest on secured loan notes. The company ended the quarter with a cash balance of $1.0 million.

Strategic Outlook Focused on Sustainable Growth and Precision Nutrition

Elixinol’s leadership remains committed to sustainable revenue growth and disciplined cost management. The Healthy Chef’s momentum is expected to continue, especially as the company advances its expansion into longevity, metabolic health, and healthy ageing through science-backed functional nutrition and bioactive peptides. This positions Elixinol to capitalise on the growing “peptide curious” consumer segment seeking non-pharmaceutical support for appetite, muscle preservation, and recovery. The company also maintains access to $4.1 million in financing facilities, with $4.04 million drawn, and recently increased its ScotPac inventory finance facility, providing additional liquidity.

Chair Gavin Evans highlighted the fundamental improvement in business quality and resilience, pointing to expanding gross margins and improved cash generation as a solid foundation for long-term value creation. The board is also exploring strategic acquisitions to complement the existing portfolio and accelerate organic growth.